nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—Angina unstable—Riluzole—amyotrophic lateral sclerosis	0.0622	0.0749	CcSEcCtD
Vardenafil—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.033	0.0397	CcSEcCtD
Vardenafil—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0325	0.0391	CcSEcCtD
Vardenafil—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.0228	0.0275	CcSEcCtD
Vardenafil—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.0226	0.0272	CcSEcCtD
Vardenafil—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.0209	0.0251	CcSEcCtD
Vardenafil—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0195	0.0235	CcSEcCtD
Vardenafil—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0178	0.0214	CcSEcCtD
Vardenafil—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.0159	0.0191	CcSEcCtD
Vardenafil—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0147	0.0178	CcSEcCtD
Vardenafil—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.0138	0.0166	CcSEcCtD
Vardenafil—Injury—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0149	CcSEcCtD
Vardenafil—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0146	CcSEcCtD
Vardenafil—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.011	0.0133	CcSEcCtD
Vardenafil—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0127	CcSEcCtD
Vardenafil—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0125	CcSEcCtD
Vardenafil—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0124	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0124	CcSEcCtD
Vardenafil—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0122	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0121	CcSEcCtD
Vardenafil—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00986	0.0119	CcSEcCtD
Vardenafil—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00986	0.0119	CcSEcCtD
Vardenafil—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0096	0.0116	CcSEcCtD
Vardenafil—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.009	0.0108	CcSEcCtD
Vardenafil—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00879	0.0106	CcSEcCtD
Vardenafil—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00879	0.0106	CcSEcCtD
Vardenafil—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00866	0.0104	CcSEcCtD
Vardenafil—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00861	0.0104	CcSEcCtD
Vardenafil—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00842	0.0101	CcSEcCtD
Vardenafil—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00838	0.0101	CcSEcCtD
Vardenafil—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00831	0.01	CcSEcCtD
Vardenafil—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00829	0.00998	CcSEcCtD
Vardenafil—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00824	0.00993	CcSEcCtD
Vardenafil—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00793	0.00955	CcSEcCtD
Vardenafil—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00791	0.00952	CcSEcCtD
Vardenafil—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00789	0.0095	CcSEcCtD
Vardenafil—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00785	0.00945	CcSEcCtD
Vardenafil—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00783	0.00943	CcSEcCtD
Vardenafil—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00779	0.00938	CcSEcCtD
Vardenafil—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00775	0.00933	CcSEcCtD
Vardenafil—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00773	0.00931	CcSEcCtD
Vardenafil—PDE6H—nervous system—amyotrophic lateral sclerosis	0.00758	0.101	CbGeAlD
Vardenafil—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00737	0.00888	CcSEcCtD
Vardenafil—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00732	0.00882	CcSEcCtD
Vardenafil—PDE6H—central nervous system—amyotrophic lateral sclerosis	0.00729	0.0975	CbGeAlD
Vardenafil—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00716	0.00862	CcSEcCtD
Vardenafil—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00713	0.00858	CcSEcCtD
Vardenafil—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00711	0.00856	CcSEcCtD
Vardenafil—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00691	0.00832	CcSEcCtD
Vardenafil—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00664	0.008	CcSEcCtD
Vardenafil—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.0066	0.00795	CcSEcCtD
Vardenafil—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00637	0.00767	CcSEcCtD
Vardenafil—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00628	0.00756	CcSEcCtD
Vardenafil—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00619	0.00746	CcSEcCtD
Vardenafil—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00617	0.00743	CcSEcCtD
Vardenafil—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00616	0.00742	CcSEcCtD
Vardenafil—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00607	0.00731	CcSEcCtD
Vardenafil—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00604	0.00727	CcSEcCtD
Vardenafil—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00595	0.00716	CcSEcCtD
Vardenafil—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00704	CcSEcCtD
Vardenafil—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00704	CcSEcCtD
Vardenafil—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00704	CcSEcCtD
Vardenafil—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00583	0.00702	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00581	0.00699	CcSEcCtD
Vardenafil—PDE11A—brain—amyotrophic lateral sclerosis	0.00579	0.0774	CbGeAlD
Vardenafil—PDE6H—brain—amyotrophic lateral sclerosis	0.00579	0.0774	CbGeAlD
Vardenafil—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00696	CcSEcCtD
Vardenafil—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00572	0.00688	CcSEcCtD
Vardenafil—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.0056	0.00675	CcSEcCtD
Vardenafil—Infection—Riluzole—amyotrophic lateral sclerosis	0.00557	0.0067	CcSEcCtD
Vardenafil—Shock—Riluzole—amyotrophic lateral sclerosis	0.00551	0.00664	CcSEcCtD
Vardenafil—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0055	0.00662	CcSEcCtD
Vardenafil—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00547	0.00659	CcSEcCtD
Vardenafil—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00655	CcSEcCtD
Vardenafil—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00542	0.00652	CcSEcCtD
Vardenafil—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00524	0.00631	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00511	0.00615	CcSEcCtD
Vardenafil—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00507	0.0061	CcSEcCtD
Vardenafil—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00606	CcSEcCtD
Vardenafil—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.005	0.00602	CcSEcCtD
Vardenafil—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00498	0.006	CcSEcCtD
Vardenafil—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00493	0.00594	CcSEcCtD
Vardenafil—PDE10A—nervous system—amyotrophic lateral sclerosis	0.00493	0.0659	CbGeAlD
Vardenafil—PDE1B—nervous system—amyotrophic lateral sclerosis	0.00488	0.0653	CbGeAlD
Vardenafil—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00484	0.00583	CcSEcCtD
Vardenafil—Pain—Riluzole—amyotrophic lateral sclerosis	0.00479	0.00577	CcSEcCtD
Vardenafil—PDE10A—central nervous system—amyotrophic lateral sclerosis	0.00474	0.0634	CbGeAlD
Vardenafil—PDE1B—central nervous system—amyotrophic lateral sclerosis	0.0047	0.0629	CbGeAlD
Vardenafil—PDE10A—cerebellum—amyotrophic lateral sclerosis	0.00464	0.062	CbGeAlD
Vardenafil—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00462	0.00556	CcSEcCtD
Vardenafil—PDE1B—cerebellum—amyotrophic lateral sclerosis	0.00459	0.0614	CbGeAlD
Vardenafil—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00552	CcSEcCtD
Vardenafil—PDE6G—Diseases associated with visual transduction—PLB1—amyotrophic lateral sclerosis	0.00456	0.0481	CbGpPWpGaD
Vardenafil—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00533	CcSEcCtD
Vardenafil—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00497	CcSEcCtD
Vardenafil—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00484	CcSEcCtD
Vardenafil—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00397	0.00477	CcSEcCtD
Vardenafil—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00383	0.00462	CcSEcCtD
Vardenafil—PDE10A—brain—amyotrophic lateral sclerosis	0.00377	0.0504	CbGeAlD
Vardenafil—PDE1B—brain—amyotrophic lateral sclerosis	0.00373	0.0499	CbGeAlD
Vardenafil—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00371	0.00446	CcSEcCtD
Vardenafil—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00429	CcSEcCtD
Vardenafil—Rash—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00426	CcSEcCtD
Vardenafil—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00425	CcSEcCtD
Vardenafil—Headache—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00423	CcSEcCtD
Vardenafil—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00333	0.00401	CcSEcCtD
Vardenafil—PDE5A—nervous system—amyotrophic lateral sclerosis	0.00288	0.0385	CbGeAlD
Vardenafil—PDE6G—beta-catenin independent WNT signaling—PFN1—amyotrophic lateral sclerosis	0.00284	0.03	CbGpPWpGaD
Vardenafil—PDE5A—central nervous system—amyotrophic lateral sclerosis	0.00278	0.0371	CbGeAlD
Vardenafil—PDE5A—cerebellum—amyotrophic lateral sclerosis	0.00271	0.0363	CbGeAlD
Vardenafil—PDE5A—brain—amyotrophic lateral sclerosis	0.0022	0.0295	CbGeAlD
Vardenafil—PDE11A—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00218	0.0231	CbGpPWpGaD
Vardenafil—PDE1B—Ca-dependent events—PLA2G4A—amyotrophic lateral sclerosis	0.00212	0.0224	CbGpPWpGaD
Vardenafil—PDE10A—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00195	0.0206	CbGpPWpGaD
Vardenafil—PDE5A—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00195	0.0206	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00181	0.0191	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00161	0.017	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00161	0.017	CbGpPWpGaD
Vardenafil—PDE1B—PLC beta mediated events—PLA2G4A—amyotrophic lateral sclerosis	0.00156	0.0165	CbGpPWpGaD
Vardenafil—PDE1B—G-protein mediated events—PLA2G4A—amyotrophic lateral sclerosis	0.00153	0.0162	CbGpPWpGaD
Vardenafil—PDE6G—Signaling by Wnt—PFN1—amyotrophic lateral sclerosis	0.0015	0.0158	CbGpPWpGaD
Vardenafil—PDE6G—Diseases associated with visual transduction—APOE—amyotrophic lateral sclerosis	0.0014	0.0148	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00125	0.0132	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00116	0.0123	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00113	0.0119	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00112	0.0118	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00112	0.0118	CbGpPWpGaD
Vardenafil—PDE6G—Disease—TPK1—amyotrophic lateral sclerosis	0.00106	0.0112	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00104	0.011	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00104	0.011	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00101	0.0106	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00101	0.0106	CbGpPWpGaD
Vardenafil—PDE1B—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000986	0.0104	CbGpPWpGaD
Vardenafil—PDE1B—Opioid Signalling—PLA2G4A—amyotrophic lateral sclerosis	0.000957	0.0101	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000909	0.0096	CbGpPWpGaD
Vardenafil—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000899	0.012	CbGeAlD
Vardenafil—PDE1B—Signaling by NGF—RTN4—amyotrophic lateral sclerosis	0.000876	0.00925	CbGpPWpGaD
Vardenafil—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000865	0.0116	CbGeAlD
Vardenafil—PDE6G—Disease—VTA1—amyotrophic lateral sclerosis	0.000844	0.00892	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000817	0.00862	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—CASP9—amyotrophic lateral sclerosis	0.00073	0.00771	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—CASP9—amyotrophic lateral sclerosis	0.000686	0.00725	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—CASP9—amyotrophic lateral sclerosis	0.000683	0.00721	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—CASP9—amyotrophic lateral sclerosis	0.00068	0.00718	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—CASP9—amyotrophic lateral sclerosis	0.000676	0.00714	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00064	0.00676	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—CASP9—amyotrophic lateral sclerosis	0.000636	0.00672	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—CASP9—amyotrophic lateral sclerosis	0.000636	0.00672	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000631	0.00666	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000626	0.00661	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.000625	0.0066	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.000625	0.0066	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.000622	0.00657	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000592	0.00625	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.000588	0.0062	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000585	0.00617	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000582	0.00614	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000579	0.00611	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PLB1—amyotrophic lateral sclerosis	0.000579	0.00611	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000568	0.006	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000566	0.00598	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000564	0.00595	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000558	0.00589	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000545	0.00576	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000545	0.00575	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000545	0.00575	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.00054	0.0057	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000535	0.00565	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000533	0.00563	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000526	0.00556	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TPK1—amyotrophic lateral sclerosis	0.000522	0.00551	CbGpPWpGaD
Vardenafil—PDE6G—Disease—VCP—amyotrophic lateral sclerosis	0.000516	0.00545	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00051	0.00538	CbGpPWpGaD
Vardenafil—CYP3A5—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000507	0.00536	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000507	0.00535	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000489	0.00517	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000486	0.00513	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000486	0.00513	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000485	0.00512	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000482	0.00509	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000455	0.00481	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000443	0.00468	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000436	0.00461	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000436	0.00461	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000433	0.00458	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000428	0.00452	CbGpPWpGaD
Vardenafil—PDE1B—Disease—VTA1—amyotrophic lateral sclerosis	0.000417	0.0044	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000417	0.0044	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000405	0.00428	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000395	0.00417	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000395	0.00417	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000383	0.00404	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000381	0.00402	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000371	0.00392	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000371	0.00392	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CST3—amyotrophic lateral sclerosis	0.00037	0.00391	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000361	0.00381	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000352	0.00372	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00035	0.00369	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000341	0.0036	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.00034	0.00359	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000336	0.00355	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000333	0.00351	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000316	0.00334	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000311	0.00328	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000307	0.00324	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000303	0.0032	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000299	0.00316	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000296	0.00313	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000296	0.00313	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PLB1—amyotrophic lateral sclerosis	0.000286	0.00302	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000283	0.00299	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000281	0.00297	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000273	0.00289	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CASP9—amyotrophic lateral sclerosis	0.000269	0.00284	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.00026	0.00274	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000257	0.00271	CbGpPWpGaD
Vardenafil—PDE1B—Disease—VCP—amyotrophic lateral sclerosis	0.000255	0.00269	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000252	0.00267	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00025	0.00264	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000248	0.00262	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000247	0.00261	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000246	0.0026	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000244	0.00257	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000236	0.00249	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000231	0.00244	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ERBB4—amyotrophic lateral sclerosis	0.00023	0.00243	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000227	0.0024	CbGpPWpGaD
Vardenafil—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000224	0.00236	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000221	0.00234	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000221	0.00233	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000217	0.00229	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000216	0.00229	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000212	0.00223	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000211	0.00223	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000206	0.00218	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000206	0.00217	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.0002	0.00211	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000198	0.00209	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000194	0.00205	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000194	0.00205	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000193	0.00204	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000189	0.00199	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000188	0.00199	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000184	0.00194	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CST3—amyotrophic lateral sclerosis	0.000183	0.00193	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000183	0.00193	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000178	0.00188	CbGpPWpGaD
Vardenafil—PDE6G—Disease—APOE—amyotrophic lateral sclerosis	0.000178	0.00188	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000176	0.00186	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000176	0.00186	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000174	0.00184	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000174	0.00184	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000173	0.00182	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000166	0.00175	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000164	0.00173	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000161	0.0017	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000161	0.0017	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000159	0.00168	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000157	0.00166	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000153	0.00162	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000152	0.0016	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000152	0.0016	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ATF1—amyotrophic lateral sclerosis	0.000151	0.0016	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.00015	0.00159	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000148	0.00156	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000148	0.00156	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000147	0.00155	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000146	0.00155	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000146	0.00155	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CASP9—amyotrophic lateral sclerosis	0.000144	0.00152	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000139	0.00147	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000136	0.00144	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000134	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CASP9—amyotrophic lateral sclerosis	0.000133	0.0014	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000131	0.00138	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000127	0.00134	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	0.000126	0.00133	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000125	0.00132	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000123	0.0013	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000123	0.0013	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTGS2—amyotrophic lateral sclerosis	0.000122	0.00129	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000122	0.00128	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000116	0.00122	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB4—amyotrophic lateral sclerosis	0.000114	0.0012	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000113	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000112	0.00118	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000106	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000104	0.0011	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000104	0.0011	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000103	0.00109	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—C3—amyotrophic lateral sclerosis	0.000102	0.00108	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000101	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—amyotrophic lateral sclerosis	9.81e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.78e-05	0.00103	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	9.53e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.31e-05	0.000983	CbGpPWpGaD
Vardenafil—PDE1B—Disease—APOE—amyotrophic lateral sclerosis	8.8e-05	0.00093	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	8.8e-05	0.000929	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.68e-05	0.000917	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.2e-05	0.000866	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	8.09e-05	0.000854	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	8.09e-05	0.000854	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.97e-05	0.000842	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.94e-05	0.000838	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.74e-05	0.000817	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.5e-05	0.000792	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.49e-05	0.000791	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—amyotrophic lateral sclerosis	7.42e-05	0.000783	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	7.4e-05	0.000781	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.37e-05	0.000778	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.31e-05	0.000772	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	7.22e-05	0.000763	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.88e-05	0.000726	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.74e-05	0.000711	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.62e-05	0.000699	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.56e-05	0.000693	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	6.47e-05	0.000683	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.16e-05	0.000651	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—amyotrophic lateral sclerosis	6.03e-05	0.000637	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5.85e-05	0.000618	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.57e-05	0.000588	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.09e-05	0.000538	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.09e-05	0.000538	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.96e-05	0.000524	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.43e-05	0.000468	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.09e-05	0.000432	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.92e-05	0.000414	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.88e-05	0.00041	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.71e-05	0.000391	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.57e-05	0.000377	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.36e-05	0.000355	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.33e-05	0.000351	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	2.94e-05	0.00031	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.51e-05	0.000265	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.01e-05	0.000212	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.81e-05	0.000191	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.66e-05	0.000175	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.36e-05	0.000144	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.35e-06	9.88e-05	CbGpPWpGaD
